Revenue: The sum of all revenue fields included for a company's operating activities.
CytomX Therapeutics, Inc. (CTMX) had Revenue of $10.26M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
|
Revenue |
$10.26M |
$-18.25M |
|
-- |
|
$10.26M |
|
$29.93M |
|
$-19.67M |
|
$1.48M |
|
$-18.19M |
|
$-18.19M |
|
$-18.25M |
|
$-18.25M |
|
$-18.25M |
|
$-18.25M |
|
$-19.67M |
|
$-20.15M |
|
177.27M |
|
177.27M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$353.10M |
|
$1.09M |
|
$6.26M |
|
$359.36M |
|
$34.02M |
|
-- |
|
$5.39M |
|
$39.41M |
|
$319.94M |
|
$318.59M |
|
$319.94M |
|
217.69M |
|
| Cash Flow Statement Financials | |
$-25.55M |
|
$-192.78M |
|
$234.49M |
|
$14.19M |
|
$30.36M |
|
$16.16M |
|
$4.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-191.77% |
|
-191.77% |
|
-- |
|
-177.32% |
|
-177.89% |
|
$-25.55M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
15.88 |
|
5.67 |
|
-5.70% |
|
-5.73% |
|
-5.08% |
|
-5.70% |
|
$1.47 |
|
$-0.14 |
|
$-0.14 |
|